Recent news includes the company's increase in buyback authorization to $10 million and extension of the plan by two years, along with insider purchases by executives and directors in early 2025. Broader market news and sector-related articles are present but do not directly update ETST's business operations.

• Earth Science Tech increased its share buyback authorization to $10 million and extended the plan by two years as of August 20, 2025 [N1].
• Insider purchases were reported with the CEO buying 100,000 shares in February 2025 and a director purchasing 100,000 shares in March 2025 [N1].
• The company has been highlighted in analyst blogs and reports with neutral recommendations in 2024 and 2025 [N1].

Earth Science Tech's integrated healthcare platform combines telemedicine and compounding pharmacy services, enhancing patient experience and operational efficiency. The company's expansion of state licensure supports broader market access. Its real estate arm provides strategic infrastructure support and capital allocation discipline. Proprietary technology in its consumer products segment offers diversification and potential for brand recognition in the direct-to-consumer market.

The company operates in highly competitive and regulated markets with significant competition from larger, well-capitalized healthcare providers and consumer brands. Regulatory compliance complexity and evolving laws may increase costs or restrict operations. Marketing effectiveness and customer retention are critical and may be challenged by privacy or healthcare laws. The company's OTC listing and penny stock status may limit liquidity and investor interest. Capital requirements and potential legal risks also pose challenges.

The company's moat derives from its vertically integrated healthcare platform that combines telemedicine consultation with proprietary compounding pharmacy fulfillment, enabling higher quality control and responsiveness compared to competitors relying on third-party pharmacies. Additionally, its real estate asset management arm supports infrastructure critical to operations, and its consumer products brand leverages proprietary intellectual property in a competitive market. High insider ownership and disciplined capital allocation further align management with shareholder interests.

• Regulatory Compliance Risks: The company operates under extensive federal, state, and local regulations across pharmacy compounding, telemedicine, consumer products, and real estate. Failure to comply could result in penalties, operational restrictions, or restructuring.
• Competitive Pressure: ETST faces competition from large healthcare systems, traditional pharmacies, digital health platforms, and established consumer product brands, which may limit its market share and growth.
• Marketing and Customer Retention: Success depends on effective marketing and retention strategies. Changes in privacy, healthcare laws, or ineffective marketing could harm business performance.
• Capital and Financial Risks: The company may require additional capital to support growth, which may not be available on acceptable terms. OTC trading and penny stock rules may affect stock liquidity and valuation.
• Legal and Litigation Risks: Potential legal proceedings, including intellectual property disputes, could result in significant costs and harm business operations.

• Earth Science Tech, Inc. (ETST) is a diversified holding company focused on the health and wellness sector headquartered in Miami, Florida, incorporated in Nevada in 2010 and redomiciled to Florida in 2022.
• The company operates a vertically integrated healthcare platform combining compounding pharmacy operations, telemedicine platforms, clinical support, and patient fulfillment.
• Primary operating subsidiaries include RxCompoundStore.com, LLC (licensed compounding pharmacy in multiple states and Puerto Rico), Mister Meds, LLC (Texas-based compounding pharmacy with sterile compounding and hazardous drug handling), Peaks Curative LLC (telemedicine referral platform for compounded medications), DOConsultation.com LLC (telehealth focused on home-based therapies), Las Villas Health Care (brick-and-mortar healthcare facility), Avenvi LLC (real estate and asset management arm supporting healthcare infrastructure and share repurchase program), and MagneChef (80%-owned direct-to-consumer kitchen products brand with proprietary IP).
• The company has expanded state licensure to reach a near-national footprint for its pharmacy and telehealth services.
• Avenvi manages real estate assets and the company's $10 million share repurchase program under SEC Rule 10b-18 safe harbor provisions.
• MagneChef operates in the competitive direct-to-consumer kitchenware market leveraging proprietary magnetic heat-conduction technology and digital marketing strategies.
• The company emphasizes fiscal discipline and shareholder alignment, with management owning approximately 48% of outstanding shares and focusing on non-dilutive financing and share buybacks.
• Operations are subject to extensive federal, state, and local regulations including pharmacy compounding laws (Section 503A FDCA), USP standards for sterile and non-sterile compounding, telemedicine regulations including COVID-19 telemedicine flexibilities through December 31, 2026, and consumer product safety and advertising regulations.
• Marketing strategies leverage vertical integration to reduce customer acquisition costs and focus on digital-first approaches for pharmacy and telehealth subsidiaries, and influencer and e-commerce marketing for MagneChef.
• The company has 77 employees as of March 31, 2026, with no union representation and good employee relations.
• Financial snapshot as of March 31, 2026: cash and equivalents $796,797; current assets $3,721,114; current liabilities $1,928,573; current ratio 1.93; cash ratio 0.41; net income $3,630,776; basic and diluted EPS $0.012.
• Revenue figure available from 2018-12-31 is $202,760 (from 10-Q filed 2019-02-27).
• The company faces competition from large healthcare providers, traditional pharmacies, digital health platforms, and established consumer product brands.
• Competitive advantage is based on vertical integration linking clinical consultation with proprietary pharmacy fulfillment for higher quality and responsiveness.
• Risks include regulatory compliance complexity, competition, marketing effectiveness, legal proceedings, capital requirements, and stock market factors such as OTC trading and penny stock rules.
• No pending or threatened legal actions likely to have material adverse effect as of filing date.
• The company has a history of net losses but reported net income in the latest fiscal year.
• Recent news coverage includes a 2025 announcement of increasing buyback authorization to $10 million and extending the plan by two years, and insider purchases by CEO and directors in early 2025.
• Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.